|
1
|
Rummel SK and Ellsworth RE: The role of
the histoblood ABO group in cancer. Future Sci OA. 2:FSO1072016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stakisaitis D, Lesauskaitė V, Girdauskaitė
M, Janulionis E, Ulys A and Benetis R: Investigation of vitamin
D-binding protein polymorphism impact on coronary artery disease
and relationship with longevity: Own data and a review. Int J
Endocrinol. 2016:83473792016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clausen H and Hakomori SI: ABH and related
histo-blood group antigens; immunochemical differences in carrier
isotypes and their distribution. Vox Sang. 56:1–20. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dean L: ABO Blood Group. In: Medical
genetics summaries [internet]. Pratt V, McLeod H, Dean L, Malheiro
A and Rubinstein W: National Center for Biotechnology Information.
Bethesda, MD; 2012, https://www.ncbi.nlm.nih.gov/books/NBK100894/Updated
2015.
|
|
5
|
Hamosh A, Scott AF, Amberger J, Bocchini
C, Valle D and McKusick VA: Online Mendelian Inheritance in Man
(OMIM), a knowledgebase of human genes and genetic disorders.
Nucleic Acids Res. 30:52–55. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto F, Cid E, Yamamoto M and Blancher
A: ABO research in the modern era of genomics. Transfus Med Rev.
26:103–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mourant AE: Blood relations: Blood groups
and anthropology. Oxford University Press; Oxford; pp. 13–20.
1983
|
|
8
|
Maynard CL, Elson CO, Hatton RD and Weaver
CT: Reciprocal interactions of the intestinal microbiota and immune
system. Nature. 489:231–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Mattos LC: Structural diversity and
biological importance of ABO, H, Lewis and secretor histo-blood
group carbohydrates. Rev Bras Hematol Hemoter. 38:331–340. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aird I, Bentall HH and Roberts JA: A
relationship between cancer of stomach and the ABO blood groups. Br
Med J. 1:799–801. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu YQ, Jiang TW, Cui YH, Zhao YL and Qiu
LQ: Prognostic value of ABO blood group in patients with gastric
cancer. J Surg Res. 201:188–195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amundadottir L, Kraft P,
Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA,
Bueno-de-Mesquita HB, Gross M, Helzlsouer K and Jacobs EJ: et
alGenome-wide association study identifies variants in the ABO
locus associated with susceptibility to pancreatic cancer. Nat
Genet. 41:986–990. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ben Q, Liu J, Wang W, Guo F, Yao W, Zhong
J and Yuan Y: Association between ABO blood types and sporadic
pancreatic neuroendocrine tumors in the Chinese Han population.
Oncotarget. 8:54799–54808. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engin H, Bilir C, Üstün H and Gökmen A:
ABO blood group and risk of pancreatic cancer in a Turkish
population in Western Black Sea region. Asian Pac J Cancer Prev.
13:131–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El Jellas K, Hoem D, Hagen KG, Kalvenes
MB, Aziz S, Steine SJ, Immervoll H, Johansson S and Molven A:
Associations between ABO blood groups and pancreatic ductal
adenocarcinoma: Influence on resection status and survival. Cancer
Med. 6:1531–1540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vasan SK, Hwang J, Rostgaard K, Nyrén O,
Ullum H, Pedersen OBV, Erikstrup C, Melbye M, Hjalgrim H, Pawitan Y
and Edgren G: ABO blood group and risk of cancer: A register-based
cohort study of 1.6 million blood donors. Cancer Epidemiol.
44:40–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hakomori S: Antigen structure and genetic
basis of histo-blood groups A, B and O: Their changes associated
with human cancer. Biochim Biophys Acta. 1473:247–266. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le Pendu J, Marionneau S, Cailleau-Thomas
A, Rocher J, Le Moullac-Vaidye B and Clément M: ABH and Lewis
histo-blood group antigens in cancer. APMIS. 109:9–31. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Franchini M, Liumbruno GM and Lippi G: The
prognostic value of ABO blood group in cancer patients. Blood
Transfus. 14:434–440. 2016.PubMed/NCBI
|
|
20
|
Freudenberg-Hua Y, Freudenberg J, Vacic V,
Abhyankar A, Emde AK, Ben-Avraham D, Barzilai N, Oschwald D,
Christen E and Koppel J: et alDisease variants in genomes of
44 centenarians. Mol Genet Genomic Med. 2:438–450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sebastiani P, Riva A, Montano M, Pham P,
Torkamani A, Scherba E, Benson G, Milton JN, Baldwin CT and
Andersen S: et alWhole genome sequences of a male and female
supercentenarian, ages greater than 114 years. Front Genet.
2:902012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fortney K, Dobriban E, Garagnani P,
Pirazzini C, Monti D, Mari D, Atzmon G, Barzilai N, Franceschi C,
Owen AB and Kim SK: Genome-wide scan informed by age-related
disease identifies loci for exceptional human longevity. PLoS
Genet. 11:e10057282015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Christensen K, Johnson TE and Vaupel JW:
The quest for genetic determinants of human longevity: Challenges
and insights. Nat Rev Genet. 7:436–448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spitsyn VA and Stakishaĭtis DV:
Interrelation of genetic dimorphism of ear wax and the level of
apolipoproteins with atherogenesis and longevity in the Lithuanian
population. Genetika. 29:334–341. 1993.(In Russian). PubMed/NCBI
|
|
25
|
Stakishaĭtis DV, Ianchauskene SM,
Ivashkiavichene LI and Priaĭksha RA: Atherogenesis and serum levels
of apolipoprotein E. Kardiologija. 32:14–16. 1992.
|
|
26
|
Stakisaitis D, Maksvytis A, Benetis R and
Viikmaa M: Coronary atherosclerosis and blood groups of ABO system
in women (own data and review). Medicina (Kaunas). 38(Suppl 2):
S230–S235. 2002.
|
|
27
|
Stini WA: Sex differences in bone loss-an
evolutionary perspective on a clinical problem. Coll Antropol.
27:23–46. 2003.PubMed/NCBI
|
|
28
|
Znaor A, Laversanne M and Bray F: Less
overdiagnosis of kidney cancer? an age-period-cohort analysis of
incidence trends in 16 populations worldwide. Int J Cancer.
141:925–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gondos A, Krilaviciute A, Smailyte G, Ulys
A and Brenner H: Cancer surveillance using registry data: Results
and recommendations for the Lithuanian national prostate cancer
early detection programme. Eur J Cancer. 51:1630–1637. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huffman DM, Deelen J, Ye K, Bergman A,
Slagboom EP, Barzilai N and Atzmon G: Distinguishing between
longevity and buffered-deleterious genotypes for exceptional human
longevity: The case of the MTP gene. J Gerontol A Biol Sci Med Sci.
67:1153–1160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
vB Hjelmborg J, Iachine I, Skytthe A,
Vaupel JW, McGue M, Koskenvuo M, Kaprio J, Pedersen NL and
Christensen K: Genetic influence on human lifespan and longevity.
Hum Genet. 119:312–321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bodmer W: Genetic characterization of
human populations: From ABO to a genetic map of the British people.
Genetics. 199:267–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garratty G, Glynn SA and McEntire R;
Retrovirus Epidemiology Donor Study: ABO and Rh(D) phenotype
frequencies of different racial/ethnic groups in the United States.
Transfusion. 44:703–706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Markt SC, Shui IM, Unger RH, Urun Y, Berg
CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM and
Giovannucci E: et alABO blood group alleles and prostate
cancer risk: Results from the breast and prostate cancer cohort
consortium (BPC3). Prostate. 75:1677–1681. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kvist E, Krogh J and Hjortberg P:
Prognostic variables in patients with prostate cancer: Influence of
blood group ABO (H), the Rhesus system, age, differentiation,
tumour stage and metastases. Int Urol Nephrol. 24:417–423. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohno Y, Ohori M, Nakashima J, Okubo H,
Satake N, Takizawa I, Hashimoto T, Hamada R, Nakagami Y, Yoshioka K
and Tachibana M: Associations between ABO blood groups and
biochemical recurrence after radical prostatectomy. Int J Clin Exp
Med. 8:2642–2648. 2015.PubMed/NCBI
|
|
37
|
Muthana SM, Gulley JL, Hodge JW, Schlom J
and Gildersleeve JC: ABO blood type correlates with survival on
prostate cancer vaccine therapy. Oncotarget. 6:32244–32256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abel PD, Marsh C, Henderson D, Leathem A,
Powell PH and Williams G: Detection of blood group antigens in
frozen sections of prostatic epithelium. Br J Urol. 59:430–435.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chastonay P, Hurlimann J and Gardiol D:
Biological tissue markers in benign and malignant disease of the
human prostate. Virchows Arch A Pathol Anat Histopathol.
410:221–229. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Q, Anver MR, Butcher DO and
Gildersleeve JC: Resolving conflicting data on expression of the Tn
antigen and implications for clinical trials with cancer vaccines.
Mol Cancer Ther. 8:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Slovin SF, Ragupathi G, Musselli C,
Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky
S, Livingston PO and Scher HI: Fully synthetic carbohydrate-based
vaccines in biochemically relapsed prostate cancer: Clinical trial
results with alpha-N-acetylgalactosamine-O-serine/threonine
conjugate vaccine. J Clin Oncol. 21:4292–4298. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hirohashi S, Clausen H, Yamada T,
Shimosato Y and Hakomori S: Blood group A cross-reacting epitope
defined by monoclonal antibodies NCC-LU-35 and −81 expressed in
cancer of blood group O or B individuals: Its identification as Tn
antigen. Proc Natl Acad Sci USA. 82:7039–7043. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Clyne M: Prostate cancer: Non-O blood type
is VTE risk factor after radical prostatectomy. Nat Rev Urol.
10:6802013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Raitanen MP and Tammela TL: Relationship
between blood groups and tumour grade, number, size, stage,
recurrence and survival in patients with transitional cell
carcinoma of the bladder. Scand J Urol Nephrol. 27:343–347. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang SS: Re: The association of ABO blood
type with disease recurrence and mortality among patients with
urothelial carcinoma of the bladder undergoing radical cystectomy.
J Urol. 196:3522016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Klatte T, Xylinas E, Rieken M, Kluth LA,
Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI and Lotan
Y: et alImpact of ABO blood type on outcomes in patients
with primary nonmuscle invasive bladder cancer. J Urol.
191:1238–1243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yamada T, Fukui I, Yokokawa M and Oshima
H: A study of prognosis and clinicopathology of bladder cancer to
blood group type of host patients in Japan. Scand J Urol Nephrol.
27:199–203. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Klatte T, Xylinas E, Rieken M, Rouprêt M,
Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino
M and Shariat SF: Effect of ABO blood type on mortality in patients
with urothelial carcinoma of the bladder treated with radical
cystectomy. Urol Oncol. 32:625–630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Süer E, Özcan C, Gökçe I, Gülpınar Ö,
Göğüş C, Türkölmez K, Baltac S and Bedük Y: Do blood groups have
effect on prognosis of patients undergoing radical cystectomy? Int
Urol Nephrol. 46:1521–1526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Foresto P, Bioindi C, Racca L, Brufman A,
Yaber F, Solis E, Provenzal O and Valverde J: Abnormal
glycosylation of soluble ABH antigens in tumors of the urinary
tract. Arch Esp Urol. 53:196–199. 2000.(In Spanish). PubMed/NCBI
|
|
51
|
Chihara Y, Sugano K, Kobayashi A, Kanai Y,
Yamamoto H, Nakazono M, Fujimoto H, Kakizoe T, Fujimoto K,
Hirohashi S and Hirao Y: Loss of blood group A antigen expression
in bladder cancer caused by allelic loss and/or methylation of the
ABO gene. Lab Invest. 85:895–907. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Engel O, Soave A, Peine S, Kluth LA,
Schmid M, Shariat SF, Dahlem R, Fisch M and Rink M: The impact of
the AB0 and the Rhesus blood group system on outcomes in bladder
cancer patients treated with radical cystectomy. World J Urol.
33:1769–1776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun W, Wen CP, Lin J, Wen C, Pu X, Huang
M, Tsai MK, Tsao CK, Wu X and Chow WH: ABO blood types and cancer
risk-a cohort study of 339,432 subjects in Taiwan. Cancer
Epidemiol. 39:150–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Joh HK, Cho E and Choueiri TK: ABO blood
group and risk of renal cell cancer. Cancer Epidemiol. 36:528–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kaffenberger SD, Morgan TM, Stratton KL,
Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA
and Clark PE: ABO blood group is a predictor of survival in
patients undergoing surgery for renal cell carcinoma. BJU Int.
110:E641–E646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
de Martino M, Waldert M, Haitel A, Schatzl
G, Shariat SF and Klatte T: Evaluation of ABO blood group as a
prognostic marker in renal cell carcinoma (RCC). BJU Int.
113:E62–E66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee C, You D, Sohn M, Jeong IG, Song C,
Kwon T, Hong B, Hong JH, Ahn H and Kim CS: Prognostic value of ABO
blood group in patients with renal cell carcinoma:
Single-institution results from a large cohort. J Cancer Res Clin
Oncol. 141:1441–1447. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Soyupek S, Tulunay O, Armağan A, Hoscan B
and Perk H: Clinical importance of intratumoral and normal renal
parenchymal inflammatory cell infiltration in renal cell carcinoma.
Scand J Urol Nephrol. 41:387–391. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Harrison ML, Obermueller E, Maisey NR,
Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C and Timotheadou E:
et alTumor necrosis factor alpha as a new target for renal
cell carcinoma: Two sequential phase II trials of infliximab at
standard and high dose. J Clin Oncol. 25:4542–4549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Melzer D, Perry JR, Hernandez D, Corsi AM,
Stevens K, Rafferty I, Lauretani F, Murray A, Gibbs JR and Paolisso
G: et alA genome-wide association study identifies protein
quantitative trait loci (pQTLs). PLoS Genet. 4:e10000722008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tirado I, Mateo J, Soria JM, Oliver A,
Martínez-Sánchez E, Vallvé C, Borrell M, Urrutia T and Fontcuberta
J: The ABO blood group genotype and factor VIII levels as
independent risk factors for venous thromboembolism. Thromb
Haemost. 93:468–474. 2005.PubMed/NCBI
|
|
62
|
Iodice S, Maisonneuve P, Botteri E, Sandri
MT and Lowenfels AB: ABO blood group and cancer. Eur J Cancer.
46:3345–3350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cordon-Cardo C, Reuter VE, Finstad CL,
Sheinfeld J, Lloyd KO, Fair WR and Melamed MR: Blood group-related
antigens in human kidney: Modulation of Lewis determinants in renal
cell carcinoma. Cancer Res. 49:212–218. 1989.PubMed/NCBI
|
|
64
|
Reid ME and Mohandas N: Red blood cell
blood group antigens: Structure and function. Semin Hematol.
41:93–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hofmann BT, Stehr A, Dohrmann T, Güngör C,
Herich L, Hiller J, Harder S, Ewald F, Gebauer F and Tachezy M:
et alABO blood group IgM isoagglutinins interact with
tumor-associated O-glycan structures in pancreatic cancer. Clin
Cancer Res. 20:6117–6126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ju T, Otto VI and Cummings RD: The Tn
antigen-structural simplicity and biological complexity. Angew Chem
Int Ed Engl. 50:1770–1791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang S, Zhang HS, Cordon-Cardo C, Reuter
VE, Singhal AK, Lloyd KO and Livingston PO: Selection of tumor
antigens as targets for immune attack using immunohistochemistry:
II. Blood group-related antigens. Int J Cancer. 73:50–56. 1997.
|
|
68
|
Hakomori S: Tumor-associated carbohydrate
antigens defining tumor malignancy: Basis for development of
anti-cancer vaccines. Adv Exp Med Biol. 491:369–402. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Williams SR, Hsu FC, Keene KL, Chen WM,
Dzhivhuho G, Rowles JL III, Southerland AM, Furie KL, Rich SS and
Worrall BB: et alGenetic drivers of von Willebrand factor
levels in an ischemic stroke population and association with risk
for recurrent stroke. Stroke. 48:1444–1450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Franchini M, Crestani S, Frattini F, Sissa
C and Bonfanti C: ABO blood group and von Willebrand factor:
Biological implications. Clin Chem Lab Med. 52:1273–1276. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Franchini M, Frattini F, Crestani S,
Bonfanti C and Lippiet G: Von Willebrand factor and cancer: A
renewed interest. Thromb Res. 131:290–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Furnari FB, Cloughesy TF, Cavenee WK and
Mischel PS: Heterogeneity of epidermal growth factor receptor
signalling networks in glioblastoma. Nat Rev Cancer. 15:302–310.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Breier G, Grosser M and Rezaei M:
Endothelial cadherins in cancer. Cell Tissue Res. 355:523–527.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Prochazka L, Tesarik R and Turanek J:
Regulation of alternative splicing of CD44 in cancer. Cell Signal.
26:2234–2239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Akhtar K, Mehdi G, Sherwani R and Sofi L:
Relationship between various cancers and ABO blood groups-a
Northern India experience. Internet J Pathol. 13:12010.
|
|
76
|
Paré G, Chasman DI, Kellogg M, Zee RY,
Rifai N, Badola S, Miletich JP and Ridkeret PM: Novel association
of ABO histo-blood group antigen with soluble ICAM-1: Results of a
genome-wide association study of 6,578 women. PLoS Genet.
4:e10001182008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang W, Xu Q, Zhuang Y and Chen Y: Novel
association of soluble intercellular adhesion molecule 1 and
soluble P-selectin with the ABO blood group in a Chinese
population. Exp Ther Med. 12:909–914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Barbalic M, Dupuis J, Dehghan A, Bis JC,
Hoogeveen RC, Schnabel RB, Nambi V, Bretler M, Smith NL and Peters
A: et alLarge-scale genomic studies reveal central role of
ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 19:1863–1872.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Paterson AD, Lopes-Virella MF, Waggott D,
Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B and
Sun L: et alGenome-wide association identifies the ABO blood
group as a major locus associated with serum levels of soluble
E-selectin. Arterioscler Thromb Vasc Biol. 29:1958–1967. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Qi L, Cornelis MC, Kraft P, Jensen M, van
Dam RM, Sun Q, Girman CJ, Laurie CC, Mirel DB and Hunter DJ: et
alGenetic variants in ABO blood group region, plasma soluble
E-selectin levels and risk of type 2 diabetes. Hum Mol Genet.
19:1856–1862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Franchini M, Favaloro EJ, Targher G and
Lippi G: ABO blood group, hypercoagulability, and cardiovascular
and cancer risk. Crit Rev Clin Lab Sci. 49:137–149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rieckmann P, Michel U, Albrecht M, Brück
W, Wöckel L and Felgenhauer K: Soluble forms of intercellular
adhesion molecule-1 (ICAM-1) block lymphocyte attachment to
cerebral endothelial cells. J Neuroimmunol. 60:9–15. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kobayashi H, Boelte KC and Lin PC:
Endothelial cell adhesion molecules and cancer progression. Curr
Med Chem. 14:377–386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Rahbari NN, Bork U, Hinz U, Leo A,
Kirchberg J, Koch M, Büchler MW and Weitz J: AB0 blood group and
prognosis in patients with pancreatic cancer. BMC Cancer.
12:3192012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ko K, Park YH, Jeong CW, Ku JH, Kim HH and
Kwak C: Prognostic significance of blood type A in patients with
renal cell carcinoma. Urol J. 13:2765–2772. 2016.PubMed/NCBI
|
|
87
|
Alkout AM, Blackwell CC and Weir DM:
Increased inflammatory responses of persons of blood group O to
Helicobacter pylori. J Infect Dis. 181:1364–1369. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Breimer ME, Mölne J, Nordén G, Rydberg L,
Thiel G and Svalander CT: Blood group A and B antigen expression in
human kidneys correlated to A1/A2/B, Lewis, and secretor status.
Transplantation. 82:479–485. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Nambiar RK, Narayanan G, Prakash NP and
Vijayalakshmi K: Blood group change in acute myeloid leukemia. Proc
(Bayl Univ Med Cent). 30:74–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ichikawa D, Handa K and Hakomori S:
Histo-blood group A/B antigen deletion/reduction vs. continuous
expression in human tumor cells as correlated with their
malignancy. Int J Cancer. 76:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Moldvay J, Scheid P, Wild P, Nabil K, Siat
J, Borrelly J, Marie B, Farré G, Labib T and Pottier G: et
alPredictive survival markers in patients with surgically
resected non-small cell lung carcinoma. Clin Cancer Res.
6:1125–1134. 2000.PubMed/NCBI
|
|
92
|
Greenwell P: Blood group antigens:
Molecules seeking a function? Glycoconj J. 14:159–173. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Halloran MM, Carley WW, Polverini PJ,
Haskell CJ, Phan S, Anderson BJ, Woods JM, Campbell PL, Volin MV,
Bäcker AE and Koch AE: Ley/H: An endothelial-selective,
cytokine-inducible, angiogenic mediator. J Immunol. 164:4868–4877.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Yamamoto F, McNeill PD and Hakomori S:
Human histo-blood group A2 transferase coded by A2 allele, one of
the A subtypes, is characterized by a single base deletion in the
coding sequence, which results in an additional domain at the
carboxyl terminal. Biochem Biophys Res Commun. 187:366–374. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cozzi GD, Levinson RT, Toole H, Snyder MR,
Deng A, Crispens MA, Khabele D and Beeghly-Fadiel A: Blood type,
ABO genetic variants, and ovarian cancer survival. PLoS One.
12:e01751192017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Trégouët DA, Heath S, Saut N,
Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika
D and Juhan-Vague I: et alCommon susceptibility alleles are
unlikely to contribute as strongly as the FV and ABO loci to VTE
risk: Results from a GWAS approach. Blood. 113:5298–5303. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ozel AB, McGee B, Siemieniak D, Jacobi PM,
Haberichter SL, Brody LC, Mills JL, Molloy AM, Ginsburg D, Li JZ
and Desch KC: Genome-wide studies of von Willebrand factor
propeptide identify loci contributing to variation in propeptide
levels and von Willebrand factor clearance. J Thromb Haemost.
14:1888–1898. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Murray S: ABO groups and Rh genotypes in
the elderly. Br Med J. 2:1472–1474. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Matsui T, Titani K and Mizuochi T:
Structures of the asparagine-linked oligosaccharide chains of human
von Willebrand factor. Occurrence of blood group A, B, and H(O)
structures. J Biol Chem. 267:8723–8731. 1992.PubMed/NCBI
|
|
100
|
Ohira T, Cushman M, Tsai MY, Zhang Y,
Heckbert SR, Zakai NA, Rosamond WD and Folsom AR: ABO blood group,
other risk factors and incidence of venous thromboembolism: The
Longitudinal Investigation of Thromboembolism Etiology (LITE). J
Thromb Haemos. 5:1455–1461. 2007. View Article : Google Scholar
|
|
101
|
Zhou S and Welsby I: Is ABO blood group
truly a risk factor for thrombosis and adverse outcomes? World J
Cardiol. 6:985–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mengoli C, Bonfanti C, Rossi C and
Franchini M: Blood group distribution and life-expectancy: A
single-centre experience. Blood Transfus. 13:313–317.
2015.PubMed/NCBI
|
|
103
|
Brecher ME and Hay SN: ABO blood type and
longevity. Am J Clin Pathol. 135:96–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Shimizu K, Hirose N, Ebihara Y, Arai Y,
Hamamatsu M, Nakazawa S, Masui Y, Inagaki H, Gondo Y and Fujimori
J: et alBlood type B might imply longevity. Exp Gerontol.
39:1563–1565. 2004. View Article : Google Scholar : PubMed/NCBI
|
